跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
Authorized
STANDARD
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
Apotex Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
cb1553df51212521
Company
Apotex Inc
Type
Standard
Approval Details
Approval Id
cb1553df51212521
Drug Approval Canada Name
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
Product Name
APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
Status
Marketed
Status Date
2018-09-04
Original Market Date
2018-09-04
Din
02468247
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
Atc Name
j 05 ar 06
Aig Number
0352327001
Company Name
Apotex Inc
Company Address
150 Signet Drive, Toronto, Ontario, Canada, M9L 1T9
Company Detail Path
/organization/apotex-inc
Company Information
Pharmaceutical Company Name
Apotex Inc
Country Name
Canada
Province Name
Ontario
City Name
toronto,ontario,country_ca
Address
150 Signet Dr
Active Ingredients
EMTRICITABINE
200 MG
TENOFOVIR DISOPROXIL FUMARATE
300 MG
EFAVIRENZ
600 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
cb1553df51212521
Type
Standard
Back to Health Canada Approvals